Claims

What is claimed is:

5

1. A method for determining inhibition of Lp-PLA2 enzyme activity in at least one sample comprising the steps of preparing a solution comprising a substrate for Lp-PLA2 comprising a colorimetric or fluorometric detectable moiety; contacting at least one said sample with the solution of the preparing step; and detecting Lp-PLA2 activity, wherein the sample is from an animal that has been administered with Lp-PLA2 inhibitor.

- 10 2. The method of claim 1, further comprising comparing Lp-PLA2 activity from at least one second sample obtained from an animal wherein said second sample is free of said Lp-PLA2 inhibitor.
- 3. The method of claim 1, wherein inhibition of Lp-PLA2 activity is measured in a plurality of samples obtained from an animal at more than one time point after administration of said Lp-PLA2 inhibitor.
 - 4. The method of claim 1, wherein the substrate is 1-myristoryl-2-(4-nitrophenylsuccinyl) phosphatidylcholine.

The method of claim 4, wherein the 1-myristoryl-2-(4-

nitrophenylsuccinyl) phosphatidylcholine is at a concentration of about 53 μM to about 1125 μM .

- 25 6. The method of claim 5, wherein the 1-myristoryl-2-(4-nitrophenylsuccinyl) phosphatidylcholine is at a concentration of about 440 μM or less.
- 7. The method of claim 5, wherein the 1-myristoryl-2-(4 30 nitrophenylsuccinyl) phosphatidylcholine is at a concentration of about 112 μM.
 - 8. The method of claim 1, wherein the sample is blood plasma.

- 9. The method of claim 1, wherein the sample is serum.
- The method of claim 6, wherein the blood plasma is diluted about 3
 to about 9 fold with the solution of the preparing step.
 - 11. The method of claim 1, wherein the Lp-PLA2 activity is measured by measuring optical density of the sample.
- 10 12. The method of claim 1, wherein the solution comprising a substrate for Lp-PLA2 further comprises a buffer and wherein the buffer is incubated with the substrate prior to contacting the substrate with said sample.
- 13. The method of claim 12, wherein the buffer does not comprise citric acid monohydrate.
 - 14. The method of claim 1, wherein the substrate concentration is maintained at approximately the Km of said substrate.
- 15. The method of claim 1, the volume of plasma sample is about 15 uL to about 50 μ L in a volume of about 125 μ L to about 170 μ L of the solution of the preparing step.
- 16. The method of claim 1, wherein the pH of the reaction is maintained at at least about 7.5 prior to contacting the sample with the solution of the preparing step.
 - 17. A method for determining Lp-PLA2 enzyme activity in a sample obtained from an animal comprising the steps of:
- c) contacting 110 μL of a solution comprising:
 a solution comprising 90 mM 1-myristoryl-2-(4-nitrophenylsuccinyl)
 phosphatidylcholine contacted with a solution comprising 200mM

HEPES, 200mM NaCl, 5mM EDTA, 10mM CHAPS, 10mM sodium 1-nonanesulfonate at a pH 7.6 in a ratio of 0.66 μ L to 110 μ L; with at least one 25 μ L tissue sample from an animal; with 25 μ L each of a p-nitrophenol standard solution comprising; 4, 3, 2, 1, 0.4 or 0.2 nmol/ μ L p-nitrophenol in methanol; and 25 μ L of phosphate buffered saline (PBS) or ddH₂O to make a blank; and

5

- d) determining Lp-PLA2 activity.
- 18. The method of claim 17, wherein the sample from animal is blood plasma.
 - 19. The method of claim 17, wherein the sample from animal is serum.
 - 20. The method of claim 17, wherein the animal is human.
 - 21. The method claim 17, wherein the animal has been administered an inhibitor of Lp-PLA2 prior to obtaining the sample.
- 22. The method of claim 21, wherein inhibition of Lp-PLA2 enzyme activity by said Lp-PLA2 inhibitor administered prior to obtaining said sample is measured by comparing Lp-PLA2 activity of a sample free of said Lp-PLA2 inhibitor.
- 25

15

- 23. The method of claim 17, further comprising:.
 - e) generating a standard curve by plotting optical density (OD) values at 405 nm for the p-nitrophenol standard solutions vs. p-nitrophenol (nmol/well);
 - f) calculating the slope (OD/nmol) of the standard curve;
- 30
- g) calculating aborbance change between 3 and 1 minute ($\Delta OD_{3min-1min}$) for both solutions comprising tissue samples and blank; and

h) calculating Lp-PLA2 activity using the following formula: $\text{Lp-PLA2 activity (nmol/min/ml)} = (\Delta \text{OD}_{\text{sample}} \text{-}\Delta \text{OD}_{\text{blank}}) \div \text{slope}$ $(\text{OD/nmol}) \div 0.025 \text{ ml} \div 2 \text{ minutes}.$